FREMONT, Calif., Feb. 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) today announced that its financial results for the fourth quarter and year ended December 31, 2005 will be released following the close of the U.S. financial markets on Monday, February 27, 2006. PDL will hold a conference call to discuss these financial results, its commercial and clinical activities and its forward-looking information and guidance with respect to future results at 4:30 p.m. Eastern time on February 27, 2006. The call will be hosted by Mr. Mark McDade, Chief Executive Officer, and Dr. Steven Benner, Senior Vice President and Chief Medical Officer.
The live webcast will be available through the PDL website: www.pdl.com. Please connect to this website at least 15 minutes prior to the live webcast to allow time for any software download that may be needed to hear the webcast. Financial and statistical information to be discussed in the call will be available on the PDL website immediately prior to the commencement of the call. A replay will be available at www.pdl.com starting approximately one hour after completion of the webcast.
An audio replay will also be available by telephone from approximately 6:30 p.m. Eastern time on February 27, 2006 through 6:30 p.m. Eastern time on March 3, 2006. To access the replay, dial 800-633-8284 from inside the United States and 402-977-9140 from outside the United States; enter conference ID number 21284399.
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life threatening illnesses. The company currently markets and sells a portfolio of leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering humanized antibody technology. Currently, PDL BioPharma's diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. For more information, please see our website at www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL BioPharma, Inc.
PDL BioPharma, Inc.CONTACT: Ami Knoefler, Senior Director, Corporate and Investor Relations,+1-510-284-8851, or ami.knoefler@pdl.com, or James R. Goff, SeniorDirector, Investor Relations, +1-510-574-1421, or james.goff@pdl.com, bothof PDL BioPharma, Inc.
Web site: http://www.pdl.com/
